An interventional study of low energy extracorporeal shockwave therapy in Chronic Prostatitis/ Pelvic Pain Syndrome, sponsored by National Taiwan University. Status unknown at 1 site in Taiwan. Open to male participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-07-10.
Sponsored by National Taiwan University · Not applicable, Interventional, and Treatment
This study is a prospective, randomized, single-blinded, cross-over trial to investigate the efficacy of low-intensity extracorporeal shockwave therapy in the treatment of chronic pelvic pain syndrome (CPPS). We will enroll 60 subjects with Chronic Prostatitis Symptom Index (CPSI) > 15. 30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses) and 30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). After 3 weeks, the two groups are cross over, for additional 6 courses. The primary outcome is the the 4th week change from baseline for CPSI score. Secondary outcomes are the 8th week change from baseline for CPSI score, IIEF, QoL; AEs. The between-group relationships of baseline and 4-week data were evaluated by using the Student's t-test or Mann-Whitney U-test where appropriate. Multiple linear regression was carried out to test the variables associated with treatment outcome. P-values \< 0.05 were considered statistically significant.
Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome.
The use of LI-ESWT has been increasingly proposed as a treatment for CPPS over the last decade. Overall, most of these studies reported encouraging results, regardless of variation in LI-ESWT set-up parameters or treatment protocols. As a whole these studies suggest that LI-ESWT could significantly improve the CPSI score and pain symptoms of CPPS patients. However, no randomized control trial with cross-over designed studies so far.
This is a prospective, randomized, single-blind, cross-over clinical study. This study will be performed in outpatient setting of NTUH. Written informed consent will be given by all participants before entering the study. The subjects are treated at the therapy room of the department of urology, NTUH. All subjects would not pay any cost for this treatment/study. This study was approved by the institutional review board at National Taiwan University Hospital (NTUH, No. T-NTUH-57401).
Inclusion criteria: were patient age 20 \~ 70 year-old man, suffering from CPPS for over 3 months, and CPSI >15. The written informed consent forms from all subjects who met the inclusion criteria were obtained.
Exclusion criteria: Patients with penile implant, prior radical prostatectomy, rectal surgery, radiation therapy to the pelvic area, spinal cord injury, prostate cancer, bladder cancer, interstitial cystitis, or major depression were excluded.
Measurement of outcomes
Primary outcome: the 4th week and the 8th week change from baseline for CPSI score.
Secondary outcomes: International Index of Erectile Function Questionnaires (IIEF) at 4th and 8th week, QoL; AEs
Methodology: All patients diagnosed of CPPS will be treated at out-patient clinic. 30 subjects receive LI-ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses) and 30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). LI-ESWT is delivered by a probe that was attached to a electrohydraulic unit with a wide-focused shockwave source. The shockwaves are delivered at perineum area. The duration of each ESWT session is about 20 minutes, and comprised 3000 pulses (0.05mJ/mm2), and a frequency of 100/min. After 3 weeks, the two groups are cross over.
Safety Considerations The peri- and post-treatment adverse events (AEs), including local pain, edema or hematoma were recorded and compared. With consideration of safety issue, any moderate/severe local pain or hematoma would be immediately reported and well inspected.
Follow-up The following parameters are assessed before treatment and weekly during the treatment: CPSI score, IIEF, QoL; AEs.
375 studies on the registry are indexed under Pelvic Pain; 89 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 277 interventional studies indexed under Pelvic Pain.
Browse Pelvic Pain studies →National Taiwan University is the lead sponsor of 22 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Suffering from CPPS over 3 months CPSI >15
Exclusion Criteria:
30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
Device: low energy extracorporeal shockwave therapy
30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
Device: low energy extracorporeal shockwave therapy
Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
CPSI score
the 4th and the 8th week change from baseline for CPSI score. 1. In the last week, have you experienced any pain / discomfort? 1. perineum 2. Testicles 3. Tip of the penis 4. pubic area 2. In the last week, have you: 1. Pain or burning during urination? 2. discomfort after sexual climax? 3. How often have you had pain over the last week? 0 Never \~ 5 Always 4. Which number describes your AVERAGE pain / discomfort over the last week? 0 \~10 5. How often have you had a sensation of not emptying your bladder completely after you finished urinating? 0 Not at all \~ 5 Almost always 6. How often have you had to urinate again \<2 hours you finished urinating? 0 Not at all \~ 5 Almost always 7. Your symptoms kept you over the last week? 0 None \~ 3 A lot 8. How much did you think about your symptoms, over the last week? 0 None \~ 3 A lot 9. If your symptoms persists during the rest of your life, how would how would you feel? 0-6
Time frame: the 4th week and the 8th week
IIEF-5 score
Over the past 6 months: How do you rate your confidence that you could get and keep an erection? (1-5) When you had erections with sexual stimulation, how often were your erections hard enough for penetration? (1-5) During sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner? (1-5) During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse? (1-5) When you attempted sexual intercourse, how often was it satisfactory for you? (1-5) Total Score: 1-7: Severe ED 8-11: Moderate ED 12-16: Mild-moderate ED 17-21: Mild ED 22-25: No ED
Time frame: the 4th week and the 8th week
Plan to share: No
Start is estimated for Oct 2019; primary completion for Mar 2020, 5 months later.
Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 5 months is below that.
Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University